On 14 August 2020, CureVac NV launched a successful IPO on the Nasdag Global Market, raising USD 213 million. The company raised a further USD 118 million in a private placement and recently completed a USD 640 million private financing round. These three transactions collectively represent equity investments of more than USD one billion. NautaDutilh acted as Dutch counsel to CureVac for the private financing round, the IPO and the private placement, alongside Davis Polk & Wardwell (US counsel) and Rittershaus (German counsel).
CureVac is a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), including an mRNA vaccine for the novel coronavirus that causes Covid-19.
NautaDutilh is proud to have been able to help CureVac reach this important milestone.